he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
查看信源地址
上一页:一文掌握癫痫用药两书
- 2022-05-04附件炎治疗和鉴别方法有哪些
- 2022-04-252013年国际抗癫痫联合会抗癫痫解毒使用指南
- 2022-04-20随之而来小儿癫痫病发病因素有哪些
- 癫痫发作对中风患者静脉溶栓的长期转移有效
- 银屑病常用药物进入医疗保险,有效减轻患者的医疗负担
- 智能手机真能成为诊断工具吗?未必!
- 移位性骶骨骨折手术后10年随访功能恢复不乐观
- 银屑病药物 Brodalumab 自杀倾向副作用AZ 遭受重创
- 寄生虫感染可能会增加儿童气道高反应的风险
- 特发性癫痫大发作药物治疗的首选
- FDA批准开浦兰治疗1个月至4岁癫痫儿童
- FDA 批准银屑病新药 ixekizumab
- 癫痫的常见症状是什么?
- 运输精子的两条路不能堵塞,4招维护指南保持畅通!
- 如何减少患者鳞屑的脱落?
- 广西百色破获药案:涉及74家药店,3000多盒
- 炎症能进行吗?
- JAMA:阳性结果的文章一定更受关注吗?
- JAAD:介绍滤泡性湿疹
- 太原东方男科医院:生殖器疱疹的传播途径
- NEJM:HIV检测、ART覆盖率和包皮环切术HIV感染风险的影响
- 治疗皮肤病的女性远离各种皮肤病
- 白癜风症状 有些白斑可以预防白癜风
- 为什么身上有小白点 可能得了这种病?
- 必须走出移动医疗「只圈地 轻盈利」怪圈
- 肾结核的最早症状?
- 癫痫治疗障碍仍难以克服
- 染发的危害 这样做可能会导致脱发
- 皮肤瘙痒不要大意!这五个迹象是由癌细胞引起的
- 临床试验显示XenoPort 银屑病药物胃肠道副作用较严重
- 如何治疗慢性鼻炎 7汤有效治疗鼻炎
- 癫痫病吃什么药性效果比较好
- 治疗腹型癫痫病只能多少钱
- 各有不同院前卒中量表的评估比较
- 痉挛的病因有很多
- 良药癫痫病症状表现
- 世界癫痫日 | 科学研究防治 规范诊疗 告别癫痫
- 7岁脑瘤患儿频发癫痫,LITT化疗避免再次开颅,如今重返校园
- 一时期癫痫病症状表现是什么
- 癫痫病人的体格检查是什么
- 引发癫痫病发病理由
- 怎么样对继发性癫痫病进行治疗
- 手术研读:内镜下经三脑室入路治疗颅内脊索瘤